Indeed, NKG2A-blockade (Monalizumab) has shown promising clinical efficacy, particularly in combination with anti-PD-1, by disrupting NKG2A-HLA-E interactions on cancer cells and reinvigorating exhausted TILs (77). This evidence concerns the gene KLRC1 and cancer.